Risk factor
Low price volatility
Profitability factor
Very strong margins and returns
About
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer;...
Company Valuation
From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, undervalu
Target Price
The average target price of IPN.PA is 121 and suggests 10% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to de
Buy
Sell